Genomic Valley Biotech Ltd - 539206 - Board Meeting Outcome for Submission Of Outcomes Of Board Meeting Held On 24Th November, 2021
Pursuant to the Regulation 30 and any other applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors at its meeting held on 24th November, 2021, has inter-alia, taken some important decisions as per attachment. Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper advertisements of the Extract of Un-Audited Financial Results for the quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09.2021 approved in Board Meeting of the Company held on 12.11.2021. Genomic Valley Biotech Ltd - 539206 - Submission Of Un-Audited Financial Results For The Quarter Ended 30.09.2021 And Year To Date From 01.04.2021 To 30.09. 2021
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09.2021 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. The above information will also be available on the Company's Website, www.genomicvalley.com . The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 12:40 P.M. Genomic Valley Biotech Ltd - 539206 - Board Meeting Outcome for Submission Of Outcomes Of Board Meeting And Un-Audited Financial Results For The Quarter Ended 30.09.2021 And Year To Date From 01.04.2021 To 30.09. 2021
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09.2021 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. The above information will also be available on the Company's Website, www.genomicvalley.com . The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 12:40 P.M. Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the Newspaper Advertisements published for the Notice of Board Meeting to be held on 12th November, 2021, inter-alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended 30th September, 2021, in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 02nd November, 2021. Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
In pursuant of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a Meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 12th November, 2021 at 11:45 A.M. inter-alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended 30th September, 2021. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons has been closed from 01st October, 2021 till 48 hours of declaration of results i.e. 14th November, 2021 (both days inclusive). Genomic Valley Biotech Ltd - 539206 - Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter And Six Months Ended September 30, 2021
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended September 30, 2021. consider and approve the Un-Audited Financial Results for the quarter and six months ended 30th September, 2021. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons has been closed from 01st October, 2021 till 48 hours of declaration of results i.e. 14th November, 2021 (both days inclusive). Genomic Valley Biotech Ltd - 539206 - Shareholding for the Period Ended September 30, 2021
Genomic Valley Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith the certificate pursuant to Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended on 30th September, 2021. Genomic Valley Biotech Ltd - 539206 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Yogesh AgrawalDesignation :- Managing Director / Whole Time Director